
C-Path’s translational therapeutics accelerator announces new grant award for drug development project in type 1 ...
TUCSON, Ariz., June 18, 2025 — Critical Path Institute’s® (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $250,000 grant award aimed at developing a novel treatment for type 1 diabetes (T1D). Kyle Apley, Ph.D., Cory …